 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

StockNews.com upgraded shares of Assembly Biosciences (NASDAQ:ASMB - Free Report) from a sell rating to a hold rating in a research report released on Friday. Separately, HC Wainwright reiterated a...

Assembly Biosciences (NASDAQ:ASMB) Lifted to Hold at StockNews.com

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) was upgraded by StockNews.com from a "sell" rating to a "hold" rating in a research note issued to investors on Friday.
Separately, HC Wainwright...

Assembly Biosciences (NASDAQ:ASMB) Rating Increased to Hold at StockNews.com

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Assembly Biosciences (ASMB Research Report), Nater...

Analysts Offer Insights on Healthcare Companies: Assembly Biosciences (ASMB), Natera (NTRA) and Disc Medicine (IRON)

Assembly Biosciences, Inc. (NASDAQ:ASMB - Get Free Report) Director John G. Mchutchison sold 1,206 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of...

Assembly Biosciences, Inc. (NASDAQ:ASMB) Director John G. Mchutchison Sells 1,206 Shares

In a report released today, Ed Arce from H.C. Wainwright maintained a Hold rating on Assembly Biosciences (ASMB Research Report). The company's s...

H.C. Wainwright Sticks to Its Hold Rating for Assembly Biosciences (ASMB)

StockNews.com downgraded shares of Assembly Biosciences (NASDAQ:ASMB - Free Report) from a hold rating to a sell rating in a research note released on Thursday morning. Assembly Biosciences Stock...

StockNews.com Lowers Assembly Biosciences (NASDAQ:ASMB) to Sell

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) was downgraded by investment analysts at StockNews.com from a "hold" rating to a "sell" rating in a note issued to investors on Thursday.
Assembly...

Assembly Biosciences (NASDAQ:ASMB) Rating Lowered to Sell at StockNews.com

InvestorPlace - Stock Market News, Stock Advice & Trading Tips
ASMB stock results show that Assembly Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
The post...

ASMB Stock Earnings: Assembly Biosciences Beats EPS for Q4 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Assembly Biosciences reports FY23 EPS ($13.38) vs. ($23.08) last year

Four candidates planned to be in clinical development in 2024 with interim data from two studies anticipated by year end Clinical development timelines accelerated for ABI-5366; now anticipating...

Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlights

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. It focuses on two innovative platform programs: oral therapeutics for the treatment of hepatitis B virus, and the oral synthetic live biotherapeutics candidate. The company was founded by Uri Lopatin and Derek A. Small on October 7, 2005 and is headquartered in South San Francisco, CA.

Volume (M)	10,221.00
52-Wk High	$20.04
52-Wk Low	$7.69

ASMB Assembly Biosciences Inc

About

Feed

News

Sentiment

Earnings

Fundamentals